
    
      This study is aimed to investigate whether treatment with Telmisartan is more effective than
      Candesartan in reducing the ischemic cardiovascular events in high-risk patients with
      cardiovascular disease.

      Study design: PROBE(Prospective, Randomized, Open-labeled Blind Endpoints)
    
  